Gameforge
The German Online Games Publisher and Developer of Popular Titles Such As Swords of Legend Online, and OGame, Tasks Stein with Spearheading its New Games Initiative
KARLSRUHE, GERMANY / ACCESSWIRE / March 30, 2022 / Today, Gameforge, online games publisher and developer of popular titles such as AION, NosTale, Metin2, Swords of Legends Online, and OGame, announced the appointment of Peter Stein as its new Director of Business Development. He will be reporting directly to the company's Chief Product Officer, Tomislav Perkovic, and leading the company's new games initiative, which is set to explore progressive takes on genre, gameplay, and mechanics, as well as exciting partnerships, diverse target audiences, and innovative technologies.
A senior professional with over ten years of experience in tech and games, Stein's notable tenures include co-founding the award-winning tech start-up Bcon as COO, and driving the licensing business at Craze Toys, working on global IPs at one of the fastest-growing toy companies in Germany. Stein began his career at Gameforge as a Sourcing Manager in 2012, responsible for finding and contracting new games development partners around the world.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page."This is an exciting opportunity, as Gameforge is taking the leap to commit serious effort into exploring new games genres. I feel honored to be given the chance to help direct and guide this effort with the support of Thomas Schöltzel and Benjamin Janson from the BizDev team," said Peter Stein. "The company's growth mindset, their value-driven company culture, and the great leadership team make me confident that together we'll continue to deliver great new games over the course of the next few years."
In all of his roles, Stein has been at the forefront of exploring and executing business development strategies, resulting in hands-on experience with companies, business models, and tools in gaming and tech, and partnerships with major brands and boutique studios. His breadth of experience made him the ideal candidate to lead Gameforge's new games initiative.
"Our Business Development team plays a major role in building the future of Gameforge," said Tomislav Perkovic, Chief Product Officer at Gameforge. "Their main task is to bring us new games and other business opportunities. We started our journey into single-player games with Trigon: Space Story, and will continue with other titles to follow soon. Of course, we are looking to broaden our portfolio not only in the amount of games, but also in different business models and platforms."
To stay up to date on all Gameforge news, follow them on Facebook, Twitter, and Linkedin, and visit gameforge.com.
A full press kit can be found here: https://uberstrategist.link/Gameforge-Corporate-PressKit
About Gameforge
Founded in 2003, Gameforge is a leading Western publisher and operator of widely acclaimed Massively Multiplayer Online (MMO) and Browser-based game titles. Gameforge builds highly active and enduring global communities by supporting players through the greatest quality LiveOps, provision of localized content, engaging community management, and frequent delivery of meaningful updates.
Gameforge's diverse portfolio of highly successful gaming brands provides different worlds with engaging experiences for players from all walks of life: core MMORPG titles Swords of Legends Online, AION, Runes of Magic, and Metin2, beloved anime MMOs Elsword and NosTale, strategy-focused browser games like OGame and Ikariam, along with indie titles such as Trigon: Space Story.
More information is available on gameforge.com
PRESS CONTACT
Lisa Mior, Michael Hruby, and James Robinson
UberStrategist Inc.
+1 646-844-8388
pr@uberstrategist.com
SOURCE: Gameforge
View source version on accesswire.com:
https://www.accesswire.com/695082/Gameforge-Hires-Peter-Stein-as-Director-of-Business-Development
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press release
Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen
Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press release
SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan
Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press release
On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press release
MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T
Datavault AI Expands IBM Collaboration to Deploy Enterprise-Grade AI at the Edge with Available Infrastructure's SanQtum AI Platform8.1.2026 13:00:00 CET | Press release
Datavault AI will activate a secured multi-city edge AI network for real-time data tokenization, security, and monetization across New York and Philadelphia NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in instant data monetization & enterprise digital twins, announced it will deliver enterprise-grade AI performance at the edge in New York and Philadelphia through an expanded collaboration with IBM using the SanQtum AI platform. Operated by Available Infrastructure, SanQtum AI is a fleet of synchronized micro edge data centers running IBM's watsonx portfolio of AI products on a zero-trust network. The combined deployment is designed to enable cybersecure data storage and compute, real-time data scoring, tokenization, and ultra-low-latency, across two of the most data-dense metro regions in the United States. By running Datavault AI's Information Data Exchange and DataScore agents - built with watsonx - within SanQtum AI's zero-trust edge e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom